咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Predictive factors of clinical... 收藏

Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis

Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis

作     者:Valeria D'Ovidio Donatella Meo Angelo Viscido Giampaolo Bresci Piero Vernia Renzo Caprilli 

作者机构:Department of Clinical SciencesGastrointestinal UnitPoliclinico Umberto IUniversity of Rome"La Sapienza"Viale del Policlinico 155Rome 00161Italy Gastrointestinal UnitAzienda Ospedaliera-Universitaria PisanaPisa 56100Italy 

出 版 物:《World Journal of Gastroenterology》 (世界胃肠病学杂志(英文版))

年 卷 期:2011年第17卷第14期

页      面:1831-1835页

核心收录:

学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主  题:溃疡性结肠炎 临床反应 单核细胞 粒细胞 预测 治疗 logistic回归模型 激素 

摘      要:AIM:To identify factors predicting the clinical response of ulcerative colitis patients to granulocyte-monocyte apheresis (GMA). METHODS:Sixty-nine ulcerative colitis patients (39 F,30 M) dependent upon/refractory to steroids were treated with GMA. Steroid dependency,clinical activity index (CAI),C reactive protein (CRP) level,erythrocyte sedimentation rate (ESR),values at baseline,use of immunosuppressant,duration of disease,and age and extent of disease were considered for statistical analysis as predictive factors of clinical response. Univariate and multivariate logistic regression models were used. RESULTS:In the univariate analysis,CAI (P = 0.039) and ESR (P = 0.017) levels at baseline were singled out as predictive of clinical remission. In the multivariate analysis steroid dependency [Odds ratio (OR) = 0.390,95% Confidence interval (CI):0.176-0.865,Wald 5.361,P = 0.0160] and low CAI levels at baseline (4 CAI 7) (OR = 0.770,95% CI:0.425-1.394,Wald 3.747,P = 0.028) proved to be effective as factors predicting clinical response. CONCLUSION:GMA may be a valid therapeutic option for steroid-dependent ulcerative colitis patients with mild-moderate disease and its clinical efficacy seems to persist for 12 mo.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分